Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for 89Zr-Trastuzumab

Philipp Mohr, Joyce van Sluis, Laura Providência, Johannes H. van Snick, Marjolijn N. Lub-de Hooge, Antoon T. Willemsen, Andor W.J.M. Glaudemans, Ronald Boellaard, Adriaan A. Lammertsma, Adrienne H. Brouwers and Charalampos Tsoumpas
Journal of Nuclear Medicine November 2023, 64 (11) 1815-1820; DOI: https://doi.org/10.2967/jnumed.123.265621
Philipp Mohr
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce van Sluis
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Providência
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes H. van Snick
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjolijn N. Lub-de Hooge
2Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoon T. Willemsen
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andor W.J.M. Glaudemans
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Boellaard
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
3Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Location VUmc, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adriaan A. Lammertsma
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrienne H. Brouwers
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charalampos Tsoumpas
1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Axial images of patient scanned on both scanners for approximately 30 min (LAFOV: Biograph Vision Quadra, SAFOV: Biograph Vision) on day 4 after injection of 37 MBq of 89Zr-trastuzumab, showing small metastasis in iliac bone (arrow). Images are shown for 2 reconstruction protocols and for reduced scan durations of 10, 5, and 3 min for LAFOV PET.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Relative differences between SAFOV and LAFOV lesion SUVmax and SUVpeak for CLIN- and EARL2-reconstructed images based on 5 patients with total of 10 lesions. Different marker (star) was used for 1 patient, because LAFOV scan duration was only 10 min instead of 30 min. CLIN SUVmax subplot has larger y-axis limits.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Relative differences between SUVmax (A), SUVpeak (B), and SUVmean (C) of healthy-tissue VOIs for SAFOV compared with LAFOV EARL2-reconstructed images. Different marker (star) was used for 1 patient, because scan duration was only 10 min instead of 30 min on LAFOV.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    COV in spheric liver VOI (3-cm diameter) in EARL2-reconstructed images for 5 patients (visualized with different colors) scanned on both SAFOV and LAFOV PET systems for approximately 30 min. One patient was scanned for only 10 min on LAFOV system, resulting in 4 patients for LAFOV-30 and LAFOV-15.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    (A and B) Tumor SUVmax (A) and SUVpeak (B) bias of lower scan durations compared with full scan duration of 30 min for EARL2 LAFOV PET, based on 25 lesions across 8 patients. (C) Healthy-tissue SUVmean bias, based on 8 patients each with 4 healthy tissue types. Solid line joins averages between scan durations.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Relative differences between SAFOV (∼30 min) and LAFOV-3 (3 min) SUVmax (A) and SUVpeak (B) of lesions for EARL2-reconstructed images, based on 5 patients with total of 10 lesions.

Additional Files

  • Figures
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (11)
Journal of Nuclear Medicine
Vol. 64, Issue 11
November 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for 89Zr-Trastuzumab
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for 89Zr-Trastuzumab
Philipp Mohr, Joyce van Sluis, Laura Providência, Johannes H. van Snick, Marjolijn N. Lub-de Hooge, Antoon T. Willemsen, Andor W.J.M. Glaudemans, Ronald Boellaard, Adriaan A. Lammertsma, Adrienne H. Brouwers, Charalampos Tsoumpas
Journal of Nuclear Medicine Nov 2023, 64 (11) 1815-1820; DOI: 10.2967/jnumed.123.265621

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for 89Zr-Trastuzumab
Philipp Mohr, Joyce van Sluis, Laura Providência, Johannes H. van Snick, Marjolijn N. Lub-de Hooge, Antoon T. Willemsen, Andor W.J.M. Glaudemans, Ronald Boellaard, Adriaan A. Lammertsma, Adrienne H. Brouwers, Charalampos Tsoumpas
Journal of Nuclear Medicine Nov 2023, 64 (11) 1815-1820; DOI: 10.2967/jnumed.123.265621
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
  • First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

Keywords

  • immuno-PET
  • zirconium
  • scan duration
  • LAFOV
  • PET/CT
SNMMI

© 2025 SNMMI

Powered by HighWire